English | Español

Abbvie
Press release submission | Jul 24, 2021

DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients

Press release submission | Aug 15, 2020

ABBVIE: New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients
Press release submission | Nov 26, 2018

ABBVIE: Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy
Press release submission | Oct 26, 2018

ABBVIE: To Assume Full Development and Commercial Control of Cystic Fibrosis Research Program
Press release submission | Sep 23, 2018

ABBVIE: Announces $5 Million Donation to Family Reach to Support Children Battling Cancer and Their Families
Carrie Bradon | Nov 28, 2017

AbbVie to take part in Evercore ISI Biopharma Catalyst conference
Kathy Adams | Nov 15, 2017

AbbVie executive to present at Jefferies London Healthcare Conference
Robert Hadley | Nov 7, 2017

FDA fast-tracking review for AbbVie’s endometriosis drug

Trending
Patient Daily | Jul 15, 2025

Scottsdale Sinus & Allergy Center garners 500+ Google reviews with a 4.9-star rating
Patient Daily | Jul 11, 2025

Physician assistant on headaches and sinusitis: ‘Sinus headaches are known to trigger your migraines’
Patient Daily | Jul 15, 2025

Gulf Coast Breathe Free Sinus & Allergy Centers earns 250+ Google reviews with a 4.9-star rating
+ Pharmaceuticals
Patient Daily | Jul 10, 2025

PhRMA Executive VP: ‘State policymakers can lead the way and must address 340B abuse and protect patients from PBMs'